CN100475270C - 一种治疗肿瘤的药物及其应用 - Google Patents

一种治疗肿瘤的药物及其应用 Download PDF

Info

Publication number
CN100475270C
CN100475270C CNB2006100112479A CN200610011247A CN100475270C CN 100475270 C CN100475270 C CN 100475270C CN B2006100112479 A CNB2006100112479 A CN B2006100112479A CN 200610011247 A CN200610011247 A CN 200610011247A CN 100475270 C CN100475270 C CN 100475270C
Authority
CN
China
Prior art keywords
seq
polyethylene glycol
endostatin
complex
complex according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2006100112479A
Other languages
English (en)
Chinese (zh)
Other versions
CN101002946A (zh
Inventor
罗永章
韩庆
雷清新
常国栋
付彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CNB2006100112479A priority Critical patent/CN100475270C/zh
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to JP2008550619A priority patent/JP5687823B2/ja
Priority to EP07702136.8A priority patent/EP1985302B1/en
Priority to US12/161,477 priority patent/US20100285103A1/en
Priority to CN201410160386.2A priority patent/CN104043107B/zh
Priority to PCT/CN2007/000204 priority patent/WO2007082483A1/zh
Priority to AU2007207268A priority patent/AU2007207268B2/en
Priority to CA2637698A priority patent/CA2637698C/en
Priority to CN200780010122.7A priority patent/CN101405019B/zh
Publication of CN101002946A publication Critical patent/CN101002946A/zh
Priority to NO20083287A priority patent/NO20083287L/no
Application granted granted Critical
Publication of CN100475270C publication Critical patent/CN100475270C/zh
Priority to JP2013036487A priority patent/JP2013163674A/ja
Priority to US16/025,315 priority patent/US20180360922A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB2006100112479A 2006-01-20 2006-01-20 一种治疗肿瘤的药物及其应用 Active CN100475270C (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CNB2006100112479A CN100475270C (zh) 2006-01-20 2006-01-20 一种治疗肿瘤的药物及其应用
CN200780010122.7A CN101405019B (zh) 2006-01-20 2007-01-19 一种治疗肿瘤的药物及其应用
US12/161,477 US20100285103A1 (en) 2006-01-20 2007-01-19 Medicament for treatment of tumors and the use thereof
CN201410160386.2A CN104043107B (zh) 2006-01-20 2007-01-19 一种治疗肿瘤的药物及其应用
PCT/CN2007/000204 WO2007082483A1 (en) 2006-01-20 2007-01-19 Medicament for treatment of tumor and the use thereof
AU2007207268A AU2007207268B2 (en) 2006-01-20 2007-01-19 Medicament for treatment of tumor and the use thereof
JP2008550619A JP5687823B2 (ja) 2006-01-20 2007-01-19 癌治療のための医薬品およびその使用
EP07702136.8A EP1985302B1 (en) 2006-01-20 2007-01-19 Medicament for treatment of tumor and the use thereof
CA2637698A CA2637698C (en) 2006-01-20 2007-01-19 Medicament for treatment of a tumor comprising a endostatin and polyethylene glycol conjugate
NO20083287A NO20083287L (no) 2006-01-20 2008-07-24 Medikament for behandling av tumorer, samt anvendelse derav
JP2013036487A JP2013163674A (ja) 2006-01-20 2013-02-26 癌治療のための医薬品およびその使用
US16/025,315 US20180360922A1 (en) 2006-01-20 2018-07-02 Medicament for treatment of tumors and the use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100112479A CN100475270C (zh) 2006-01-20 2006-01-20 一种治疗肿瘤的药物及其应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2009101322177A Division CN101596320B (zh) 2006-01-20 2006-01-20 一种治疗肿瘤的药物及其应用
CN 201210564574 Division CN103083681A (zh) 2006-01-20 2006-01-20 一种治疗肿瘤的药物及其应用

Publications (2)

Publication Number Publication Date
CN101002946A CN101002946A (zh) 2007-07-25
CN100475270C true CN100475270C (zh) 2009-04-08

Family

ID=38287273

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB2006100112479A Active CN100475270C (zh) 2006-01-20 2006-01-20 一种治疗肿瘤的药物及其应用
CN201410160386.2A Active CN104043107B (zh) 2006-01-20 2007-01-19 一种治疗肿瘤的药物及其应用
CN200780010122.7A Active CN101405019B (zh) 2006-01-20 2007-01-19 一种治疗肿瘤的药物及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201410160386.2A Active CN104043107B (zh) 2006-01-20 2007-01-19 一种治疗肿瘤的药物及其应用
CN200780010122.7A Active CN101405019B (zh) 2006-01-20 2007-01-19 一种治疗肿瘤的药物及其应用

Country Status (8)

Country Link
US (2) US20100285103A1 (enExample)
EP (1) EP1985302B1 (enExample)
JP (2) JP5687823B2 (enExample)
CN (3) CN100475270C (enExample)
AU (1) AU2007207268B2 (enExample)
CA (1) CA2637698C (enExample)
NO (1) NO20083287L (enExample)
WO (1) WO2007082483A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013034116A1 (zh) 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体
CN106924754A (zh) * 2015-12-30 2017-07-07 北京大学 聚氨基酸偶联物

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961831B (zh) * 2007-09-05 2020-06-23 江苏先声药业有限公司 一种修饰的重组人内皮抑素及其应用
CN101396347B (zh) * 2007-09-27 2011-12-14 江苏先声药物研究有限公司 一种重组人血管内皮抑制素缓释微球的制备方法
CN101265298B (zh) * 2008-04-30 2011-11-09 中国药科大学 含有非天然氨基酸的内皮抑素突变体及其衍生物
CN101642559B (zh) * 2008-06-30 2012-08-01 江苏先声药物研究有限公司 含微粉化人血管内皮抑制素的药物组合物
US8507441B2 (en) 2009-10-22 2013-08-13 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Use of endostatin peptides for the treatment of fibrosis
JP2013523726A (ja) * 2010-04-01 2013-06-17 オンコレナ エービー 腎細胞癌の改良された治療
CN101890155B (zh) * 2010-05-25 2012-07-25 江苏先声药物研究有限公司 一种药物组合物及其应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
CN104031261B (zh) * 2014-06-20 2017-10-27 电子科技大学 温敏性共聚物及其水凝胶体系
CN104174015A (zh) * 2014-08-22 2014-12-03 广州安辰医药科技有限公司 疫苗组合物及其在肿瘤治疗中的用途
CN104515768B (zh) * 2014-08-29 2017-01-25 湖南新大陆生物技术有限公司 一种肿瘤特异性生长因子检测试剂盒
CN104771603B (zh) * 2015-04-17 2018-05-18 张坤镛 一种改善唾液酸异常的中药口服药及制备方法
CN105646701B (zh) * 2016-03-29 2019-03-05 徐根兴 不同氨基酸结构的重组人内皮抑素蛋白及其制备方法和应用
CN107865824B (zh) * 2016-09-28 2020-04-03 山东先声生物制药有限公司 一种稳定的重组人血管内皮抑制素皮下注射组合物
US11098104B2 (en) * 2016-11-10 2021-08-24 Beijing Protgen Ltd. Pegylated endostatin analogue and application thereof
CA3103035A1 (en) * 2017-07-30 2019-02-07 Tsinghua University Medication for inhibiting dna-pkcs
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN110870869A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含糖类营养素和常规无效化合物的药物组合物及其应用
WO2022161381A1 (zh) * 2021-01-26 2022-08-04 清华大学 血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用
CN113350576A (zh) * 2021-05-21 2021-09-07 上海大学 快慢交联互补的双网络自愈合可注射水凝胶及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067971A2 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of endostatin in the treatment of ocular neovascularization
CN1443194A (zh) * 2000-05-16 2003-09-17 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
CN1646154A (zh) * 2002-02-07 2005-07-27 达尔塔生物技术有限公司 与白蛋白融合的抗－血管生成肽
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911929A (en) 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
DK1053012T3 (da) 1998-02-09 2003-11-17 Enzon Pharmaceuticals Inc Farmaceutiske sammensætninger omfattende PEG-asparaginase til behandling af HIV-infektioner
US6689762B1 (en) 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
EA004789B9 (ru) * 1998-10-16 2017-05-31 Байоджен, Инк. Полимерные конъюгаты бета-1а-интерферона и их использование
US7582301B1 (en) 1999-05-17 2009-09-01 Conjuchem Biotechnologies, Inc. Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
JP2003508501A (ja) 1999-09-07 2003-03-04 コンジュケム，インコーポレーテッド 生物学的結合のための肺送達
AU2001289132A1 (en) * 2000-11-28 2002-06-11 Phoenix Pharmacologics, Inc. Modified arginine deiminase
RU2294938C2 (ru) * 2002-07-24 2007-03-10 Ф.Хоффманн-Ля Рош Аг Пэгилированный полипептид т1249
CA2496820A1 (en) * 2002-08-28 2004-03-11 Novartis Ag Ocular gene therapy
US7078485B2 (en) * 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
JP2006519235A (ja) 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
ATE412745T1 (de) * 2003-08-29 2008-11-15 Childrens Medical Center Antiangiogene peptide vom n-terminus von endostatin
JP4762904B2 (ja) 2003-11-13 2011-08-31 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン不変領域の量産方法
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
CN100355784C (zh) 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
JP2005245269A (ja) 2004-03-03 2005-09-15 Nipro Corp 血清アルブミン多量体を含む遺伝子組換え型蛋白質
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
CN1311867C (zh) 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1443194A (zh) * 2000-05-16 2003-09-17 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
WO2002067971A2 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of endostatin in the treatment of ocular neovascularization
CN1646154A (zh) * 2002-02-07 2005-07-27 达尔塔生物技术有限公司 与白蛋白融合的抗－血管生成肽
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013034116A1 (zh) 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体
CN106924754A (zh) * 2015-12-30 2017-07-07 北京大学 聚氨基酸偶联物
CN106924753A (zh) * 2015-12-30 2017-07-07 北京大学 制备蛋白质‑聚氨基酸环状偶联物的方法
CN106924752A (zh) * 2015-12-30 2017-07-07 北京大学 制备蛋白质‑聚氨基酸偶联物的方法
CN106924754B (zh) * 2015-12-30 2021-11-09 北京大学 聚氨基酸偶联物
CN106924753B (zh) * 2015-12-30 2021-11-09 北京大学 制备蛋白质-聚氨基酸环状偶联物的方法
CN106924752B (zh) * 2015-12-30 2021-11-09 北京大学 制备蛋白质-聚氨基酸偶联物的方法

Also Published As

Publication number Publication date
US20180360922A1 (en) 2018-12-20
CA2637698A1 (en) 2007-07-26
CN104043107B (zh) 2016-09-07
US20100285103A1 (en) 2010-11-11
CN101405019B (zh) 2014-06-04
NO20083287L (no) 2008-10-20
AU2007207268A1 (en) 2007-07-26
EP1985302A1 (en) 2008-10-29
WO2007082483B1 (en) 2007-09-07
WO2007082483A1 (en) 2007-07-26
JP2009523743A (ja) 2009-06-25
CN101002946A (zh) 2007-07-25
CN104043107A (zh) 2014-09-17
EP1985302B1 (en) 2018-01-03
JP2013163674A (ja) 2013-08-22
JP5687823B2 (ja) 2015-03-25
AU2007207268B2 (en) 2011-08-18
CA2637698C (en) 2016-09-20
EP1985302A4 (en) 2013-01-02
CN101405019A (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
CN100475270C (zh) 一种治疗肿瘤的药物及其应用
CA2675231C (en) A conjugate comprising angiostatin or its fragment, the method for producing the conjugate and use thereof
WO2007082482A1 (en) Novel compound for treatment of tumor
JP7140454B2 (ja) ペグ化エンドスタチン類似体およびその適用
CN101544696A (zh) 含色素上皮衍生因子的复合物及其制备方法和应用
CN103083681A (zh) 一种治疗肿瘤的药物及其应用
CN101596320B (zh) 一种治疗肿瘤的药物及其应用
AU2012203658B2 (en) Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof
HK1122498A (en) Medicament for treatment of tumor and the use thereof
HK1122498B (en) Medicament for treatment of tumor and the use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20070725

Assignee: Beijing Pro Pharmaceutical Technology Co., Ltd.

Assignor: Tsinghua University|Beijing Progi Biotechnology Development Co., Ltd.

Contract record no.: 2017990000176

Denomination of invention: Medicine for treating tumor, and its application

Granted publication date: 20090408

License type: Exclusive License

Record date: 20170511

EE01 Entry into force of recordation of patent licensing contract